Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer immunotherapy, but secondary resistance (SR) and immune-related adverse events (irAEs) are significant clinical dilemmas. Although the gut microbiota is associated with ICI efficacy and irAEs, the knowledge of longitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yanlin, Shi, Qingya, Liu, Xinyu, Tang, Hao, Lu, Bo, Zhou, Qingyang, Xu, Yan, Chen, Minjiang, Zhao, Jing, Li, Yue, Qian, Jiaming, Wang, Mengzhao, Tan, Bei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126279/
https://www.ncbi.nlm.nih.gov/pubmed/37114123
http://dx.doi.org/10.3389/fonc.2023.1144534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126279/
https://www.ncbi.nlm.nih.gov/pubmed/37114123
http://dx.doi.org/10.3389/fonc.2023.1144534

Ejemplares similares